Medical University of South Carolina - Hollings Cancer Center
Medical University of South Carolina - Hollings Cancer Center
Charleston, South Carolina, United States5 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Phase II Palbociclib +Ibrutinib in Mantle Cell Lymphoma | B-cell neoplasm, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, mantle cell lymphoma, neoplasm | Active, not recruiting | Phase 2 | 2026-10-02 | NCT03478514 | |
| A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma | Disease Attributes, Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, astrocytoma (excluding glioblastoma), epithelial neoplasm, glioblastoma, glioma, neoplasm, neuroepithelial neoplasm, primitive neuroectodermal tumor | Recruiting | Phase 2 / Phase 3 | 2026-10-01 | NCT03970447 | |
| Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC | Locally Advanced Pancreatic Cancer | Active, not recruiting | Phase 3 | 2026-09-30 | NCT03257033 | |
| Study of JANX014 in Subjects With Metastatic Castration-Resistant Prostate Cancer | Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate cancer, prostate disorder | Recruiting | Phase 1 | 2026-09-03 | NCT07545811 | |
| Durvalumab With Radiotherapy for Adjuvant Treatment of Intermediate Risk SCCHN | Head and Neck Neoplasms, Mouth Neoplasms, Neoplasms by Site, Stomatognathic Diseases, laryngeal disorder, lymphoid interstitial pneumonia, mouth disorder, neoplasm, otorhinolaryngologic disease, respiratory system disorder | Active, not recruiting | Phase 2 | 2026-06-23 | NCT03529422 |